Tuberculosis
Conditions
Keywords
Early bactericidal activity, Pulmonary tuberculosis, RIFAFOUR, Bedaquiline, Delamanid, GSK3036656, BTZ-043
Brief summary
This study aims to measure the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics with GSK3036656 in combination with either delamanid or bedaquiline or BTZ-043, delamanid in combination with bedaquiline or standard of care for 14 days in participants with newly diagnosed sputum smear positive drug-sensitive pulmonary tuberculosis. Participants will revert to the standard treatment (RIFAFOUR® e-275) once the study treatment (Day 1 to Day 14) has been completed.
Interventions
DRUGGSK3036656
GSK3036656 will be administered.
DRUGBedaquiline
Bedaquiline will be administered.
DRUGDelamanid
Delamanid will be administered.
DRUGRIFAFOUR e-275
RIFAFOUR e-275 will be administered.
DRUGBTZ-043
BTZ-043 will be administered.
Sponsors
Click-TB Consortium
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)
Masking description
All laboratory staff involved in analyzing and reporting the microbiological endpoints (logarithm to base10 \[log10\] colony forming units \[CFU\] counts and time to sputum culture positivity) will be unaware of treatment assignments.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Participants must be 18 to 65 years of age inclusive, at the time of signing the informed consent. * Participants who have: 1. New episode of untreated, rifampicin-susceptible pulmonary tuberculosis (TB) 2. A chest X-ray picture consistent with pulmonary TB 3. At least one sputum sample positive on direct microscopy for acid-fast bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/World Health Organization \[WHO\] scale) or positive on a molecular test (at least medium positive for MTB on Xpert MTB/Rif) 4. Normal echocardiogram or echocardiogram with normal left ventricular function with at most trace to mild valvular regurgitation is allowed and no valvular stenosis. 5. A creatinine clearance greater than or equal to (\>=)90 mL/minute (Cockroft-Gault formula). * Male participants are eligible to participate if they agree to barrier precautions until 90 days after last dose. * A female participant is eligible to participate if she is not pregnant or breast feeding and is a woman of non-childbearing potential (WONCBP) or a woman of childbearing potential (WOCBP) using a contraceptive method that is highly effective. A WOCBP must have a negative pregnancy test urine or serum as required by local regulations before the first dose of study intervention. Only participants who are at least 25 years of age (and females of non-childbearing potential) will be eligible for the positron emission tomography-computed tomography (PET-CT) assessments. * Capable of giving signed informed consent.
Exclusion criteria
* Evidence of a clinically significant (as judged by the Investigator) condition or abnormality (other than the indication being studied) that might compromise safety or the interpretation of trial efficacy or safety endpoints. * Clinically significant evidence of extrathoracic TB as judged by the Investigator. * QTc interval corrected for heart rate by Fridericia's formula (QTcF) greater than (\>)450 milliseconds (msec). * Arterial hypertension with Systolic BP \>=160 mm Hg or diastolic BP \>=100 nm Hg. Participants with well-controlled hypertension may be included if they are using amlodipine for the duration of the study. * Participants with vitiligo. * Participants receiving any QT prolonging drugs, including but not limited to fluoroquinolones, macrolides and clofazimine. * HIV infected participants: 1. having a cluster of differentiation (CD)4+ count \<350 cells/microliters; 2. having received any antiretroviral therapy medication within the last 30 days; 3. or having received oral or intravenous antifungal medication within the last 30 days; 4. or with an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection or malignancies in the last 12 months (except pulmonary TB). * Presence of Hepatitis B surface antigen (HBsAg) or Positive Hepatitis C antibody test result at screening. * Participants with diabetes (Type 1 or 2), point of care glycated hemoglobin (HbA1c) above 6.5%, or random glucose over 11.1 millimoles (mmol)/L * Any diseases or conditions in which use of delamanid or bedaquiline is contraindicated. * Participants with abnormal laboratory values at screening as graded by the enhanced Common Terminology Criteria for Adverse Events (CTCAE version 5 2017).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in log10 CFU of Mycobacterium tuberculosis (MTB) (per milliliters of respiratory sputum samples) | Baseline and up to Day 14 | The extended early bactericidal activity of each treatment group will be determined by the change from Baseline to Day 14 in log10CFU. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with serious adverse events | Up to Day 28 | — |
| Number of participants with adverse events of Grade 3 severity or higher | Up to Day 28 | — |
| Number of participants with adverse events related to study drug | Up to Day 28 | — |
| Number of participants withdrawn from the treatment due to adverse events | Up to Day 28 | — |
| Change from Baseline in time to sputum culture positivity | Baseline and up to Day 14 | Time to sputum-culture positivity is the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. |
| Number of participants with electrocardiogram (ECG) values of potential clinical importance (PCI) | Up to Day 28 | — |
| Number of participants with hematology laboratory values of PCI | Up to Day 28 | — |
| Number of participants with clinical chemistry laboratory values of PCI | Up to Day 28 | — |
| Number of participants with vital signs of PCI | Up to Day 28 | — |
| Number of participants withdrawn from the study due to adverse events | Up to Day 28 | — |
Countries
South Africa
Outcome results
None listed